Abstract The oncoprotein MDM2 (murine double minute 2) is often overexpressed in human tumors and thereby attenuates the function of the tumor suppressor p53. In this study, we investigated the effects of the novel MDM2-inhibitor PXN727 on p53 activation, cell proliferation, cell cycle distribution and radiosensitivity. Since the localization of heat shock protein 70 (Hsp70) exerts different effects on radioresistance of tumor cells, we investigated the impact of PXN727 on intracellular, membrane, and secreted Hsp70 levels. We could show that PXN727 exerts its effects on wildtype p53 (HCT116 p53 +/+ , A549) but not p53 depleted (HCT116 p53 −/− ) or mutated (FaDu) tumor cells. PXN727 activates p53, induces the expression of p21, reduces the proportion of cells in the radioresistant S-phase and induces senescence. Radiosensitivity was significantly increased by PXN727 in HCT116 p53 +/+ tumor cells. Furthermore, PXN727 causes a downregulation of Hsp70 membrane expression and an upregulated secretion of Hsp70 in wildtype p53 tumor cells. Our data suggest that re-activation of p53 by MDM2-inhibition modulates Hsp70 membrane expression and secretion which might contribute to the radiosensitizing effect of the MDM2-inhibitor PXN727.
Introduction
Radiotherapy is one of the key treatment modalities to cure solid tumors, but its efficacy is limited by radioresistant tumor cell clones and normal tissue toxicity. Therefore, there is a high medical need to develop agents that sensitize tumor cells to ionizing radiation (IR) in a highly specific manner. However, currently no clinically applied radiosensitizers are available.
The tumor suppressor gene p53 is a transcription factor that is crucial for cellular pathways regulating DNA repair, cell cycle and apoptosis in response to irradiation. Upon activation, p53 induces the synthesis of its negative regulator MDM2 (murine double minute 2) that binds to p53 and induces its proteasomal degradation (Shangary and Wang 2008) . This autoregulatory feedback loop tightly controls p53 protein levels in normal cells. However, in human tumor cells, MDM2 is frequently overexpressed and thus leads to inhibition of p53-signaling. As a result these tumor cells are impaired in inducing cell cycle arrest and apoptosis, and thus are more radioresistant (Gudkov and Komarova 2003) .
Targeting the MDM2-p53 interaction by small molecule inhibitors is a promising strategy to restore the tumor suppressor and pro-apoptototic activity of p53 (Shangary and Wang 2008) . Nutlin-3 is one of the first MDM2-antagonists that activates p53 and sensitizes tumor cells to IR in a non-genotoxic manner (Arya et al. 2010; Cao et al. 2006; Impicciatore et al. 2010; Supiot et al. 2008) . Recently, novel isoquinolin-1-one based derivatives (PXN) have been developed as inhibitors of the p53-MDM2 interaction. They exhibit a better oral bioavailability, lower toxicity, more specific binding to the N-terminal binding site of MDM2 and an easier chemical synthesis compared to Nutlin-3 (Rothweiler et al. 2008) .
In the present study, the compound PXN727 was analyzed with respect to its capacity to affect cell proliferation, cell cycle distribution, senescence, radiosensitivity and the stress response in wildtype (WT) and mutant p53 tumor cells. Similar to Nutlin-3, PXN727 significantly reduces the proportion of cells in the radioresistant S-phase, inhibits cell proliferation, induces senescence and increases the sensitivity of WT but not mutant p53 tumor cells to IR. The stress-inducible, cytoprotective heat shock protein 70 (Hsp70) is frequently overexpressed in the cytosol of radioresistant tumor cells. Different environmental stress factors (e.g., heat shock, nutrient deprivation) but also therapeutic interventions such as IR, hyperthermia, and chemotherapy further increase the synthesis of Hsp70. In contrast to normal cells, Hsp70 also can be found on the plasma membrane and in the extracellular milieu of tumor cells (Multhoff et al. 1995; Sherman and Multhoff 2007) . It appeared that membrane Hsp70 contributes to radio-and chemoresistance of tumors , whereas extracellular located Hsp70 can promote tumor cell death (Schilling et al. 2009 ). In line with these results, herein, we observed a PXN727-mediated downregulation of Hsp70 on the plasma membrane, an increased release of Hsp70 into the extracellular environment and an enhanced radiosensitivity in WT but not mutant p53 tumor cells. Taken together, these results suggest that re-activation of p53 by MDM2-inhibitor PXN727 reduces membrane density of Hsp70 and increases Hsp70 secretion which might contribute to the radiosensitizing effect of PXN727. −/− tumor cells were treated with PXN727 or Nutlin-3 (10 μM each) for 24 h. Protein expression levels were analyzed by Western blot analysis using antibodies directed against p53, p21 and MDM2. β-actin was used as loading control 
Materials and methods

Cells
Treatment with MDM2-inhibitors and irradiation
Ten millimolar stock solutions of Nutlin-3 (Sigma) and PXN727 (kindly provided by Priaxon, München, Germany) were prepared in 100 % DMSO. Further dilutions were performed in PBS. As a control, DMSO diluted in PBS in the respective concentration was used in all experiments. Tumor cells were irradiated with the indicated doses using the RT100 irradiation device (Philips) at a dose rate of 1 Gy/min. Control cells were sham irradiated at 0 Gy.
ELISA and western blot analysis
Cells were lysed in TBST buffer (1 % Triton X-100 in TBS, 1 mM PMSF, protease inhibitor cocktail) and protein content determined using the BCA™ Protein Assay Kit (Pierce). Hsp70 concentrations in cell lysates and in cell culture supernatants were determined by ELISA according to the manufacturer's instructions (R&D).
For Western Blot analysis, proteins were detected with monoclonal antibodies directed against Hsp70 (SPA-810, Assay Designs), p53 (BD Biosciences), p21 and MDM2 (Merck), and β-actin (Sigma). Bound antibodies were visualized using horseradish peroxidase-conjugated secondary antibodies (Promega) and a chemiluminescence developing kit (ECL, Amersham Biosciences).
Flow cytometry
Trypsinized cells (100,000) were incubated with the FITCconjugated Hsp70 monoclonal antibody cmHsp70.1 (multimmune GmbH, Munich, Germany) or the corresponding isotype-matched control antibody (IgG1, BD Biosciences) for 30 min at 4°C. Dead cells were stained with propidium iodide (PI, Sigma-Aldrich), and viable cells were analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Proliferation assay
Cells were seeded into 96-well plates (4,000 cells/well). Twenty-four hours after seeding, various concentrations of PXN727 or Nutlin-3 were added, and cells were incubated for further 72 h. The proliferation was measured using the MTS-assay according to the manufacturer's instructions (Promega).
Cell cycle analysis
For analysis of cell cycle distribution, cells were collected by trypsinization and fixed with ice-cold 70 % ethanol at −20°C.
After washing in PBS, cells were resuspended in 500 μl PI/ RNase staining solution (Sigma-Aldrich), incubated for 60 min at room temperature and analyzed using FACSCalibur flow cytometer. The cell cycle distribution was calculated by using Modfit software (Verity software house Inc).
Clonogenic cell survival assay Cells were treated with 10 μM PXN727 or Nutlin-3 and 1 h later irradiated. Twenty-four hours after irradiation, cells were collected by trypsinization, counted and seeded into 12-well plates. On days 6-8 after seeding, colonies were fixed in methanol, stained with crystal violet and counted. Survival curves were fitted to the linear quadratic model using Sigmaplot (Systat Software Inc). The sensitizing enhancement ratio (SER) was defined as SER 0D 5 0 (irradiation)/D 50 (drug and irradiation).
β-galactosidase assay
Staining of β-galactosidase (β-gal) in tumor cells was performed using the senescence β-galactosidase staining kit (Cell Signaling Technology) according to the manufacturer's protocol.
Statistics
Statistical analysis was performed using SPSS 18.0.2 software. The Student's t test was used to evaluate significant differences (*p≤0.05, **p≤0.01, ***p≤0.001).
Results
PXN727 inhibits cell proliferation, re-activates p53 and induces a cell cycle arrest in WT p53 tumor cells
To examine the p53-dependency of PXN727, two isogenic colon cancer cell lines were chosen that differ in their p53 status; HCT116 WT p53 (p53 +/+ ) and p53 null mutant (p53
). PXN727 decreased the proliferation of HCT116 p53 +/+ with an IC 50 value of 2 μM, but not that of the HCT116 p53 − / − tumor cells (Fig. 1a) . The antiproliferative activity of PXN727 in p53 +/+ tumor cells was comparable to that of Nutlin-3 (IC 50 : 2.5 μM) (Fig. 1b) . However, at concentrations higher than 10 μM, Nutlin-3 showed a p53-independent anti-proliferative effect also in HCT116 p53
−/− tumor cells. For all further experiments, PXN727 and Nutlin-3 were applied at a maximum concentration of 10 μM. PXN727, as well as Nutlin-3, induced an accumulation of p53 and a robust upregulation of the p53 target genes p21 and MDM2 in HCT116 p53 +/+ but not in p53 −/− tumor cells (Fig. 2) . This indicates that PXN727 is as effective as Nutlin-3 in activating the p53 pathway. Since p53 and p21 play a major role in cell cycle regulation, we studied the PXN727-mediated effects on cell cycle distribution. In HCT116 p53 +/+ tumor cells, PXN727 significantly decreased the proportion of cells in the radioresistant Sphase and induced an increase in the G 1 -and G 2 /M-phase (Fig. 3b) . In line with the results of other groups (Cao et al. 2006; Miyachi et al. 2009 ), comparable effects on cell cycle distribution were observed when these cells were treated with Nutlin-3 (Fig. 3b) . The decrease in the S-phase following treatment with both MDM2 inhibitors was confirmed in the WT p53 lung cancer cell line A549 (Fig. 3c) . HCT116 p53 −/− tumor cells (Fig. 3b) and the mutant p53 tumor cell line FaDu (Fig. 3c) , showed a weak reduction in the proportion of cells in the S-phase after treatment with PXN727, whereas Nutlin-3 showed no alterations in the cell cycle.
Several studies have shown that IR increases the expression of MDM2 in a p53-dependent manner and thereby attenuates p53 functions such as the induction of the cell cycle arrest (Impicciatore et al. 2010) . Therefore, we wanted to determine how the inhibition of MDM2 in combination with IR affects the cell cycle distribution. HCT116 p53 +/+ and p53 −/− tumor cells were treated with either PXN727 or Nutlin-3 followed by IR with 4 Gy (Fig. 3b) . IR alone induced a comparable increase of cells in the G 2 /M-phase in both cell lines and a slight decrease of cells in the S-and G 1 -phase. Interestingly, in p53 +/+ cells the combination of PXN727 and IR induced a synergistic effect on the G 2 /M-arrest. Similar but less pronounced effects were induced by Nutlin-3. In p53 −/− cells, pre-treatment of the cells with both MDM2-inhibitors did not impact the IR-induced effects.
PXN727 radiosensitizes colon cancer cells containing WT p53
Irrespective of the p53-status, HCT116 p53 +/+ and p53
tumor cells showed a comparable sensitivity towards IR (Fig. 4) . Although PXN727 (SER 02.3) and Nutlin-3 (SER02.4) significantly enhanced the radiosensitivity of HCT116 WT p53 cells, no radiosensitizing effects were observed in HCT116 tumor cells lacking p53 (SER01.0 for PXN727 and 1.1 for Nutlin-3). These data demonstrate for the first time that the new MDM2-inhibitor PXN727 increases the radiosensitivity of tumor cells by reactivation of WT p53.
PXN727 induces senescence in colon cancer cells containing WT p53
To determine the mechanism by which PXN727 mediates radiosensitization, we investigated apoptosis and cellular senescence as potential p53-dependent pathways in the isogenic HCT116 cell system. In accordance to published data (Arya et al. 2010; Lehmann et al. 2007) , apoptosis was only marginally induced in HCT116 WT p53 cells by PXN727 or Nutlin-3 at a concentration of 10 μM (data not shown). However, PXN727 and Nutlin-3 caused senescence in HCT116 WT p53 cells, as shown by reduced cell proliferation, increased cell size and induction of β-galactosidase expression (Fig. 5) . In contrast, no signs of senescence were observed after an identical treatment in HCT116 cells that lack p53. In line with the literature (Jackson et al. 2012) , doxorubicin which was used as a positive control in our experiments, also induced cellular senescence in HCT116 WT p53 cells (data not shown). p53-dependent reduction of cell surface Hsp70 upon PXN727 treatment Dependent on its subcellular/extracellular localization, Hsp70 is known to exert different effects with regard to radioresistance. Therefore, we investigated whether changes in radiosensitivity upon MDM2-inhibition might be associated with altered Hsp70 levels. As shown by Western Blot analysis and ELISA the cytosolic Hsp70 levels remained unaltered upon MDM2-inhibition in both tumor sublines (Fig. 6) .
Dose [Gy
The cell surface expression of Hsp70 was measured by flow cytometry using the Hsp70-specific monoclonal antibody cmHsp70.1 (Fig. 7a+b) . Under standard conditions both HCT116 sublines barely differed in their Hsp70 membrane expression (45 vs. 50 %). In HCT116 p53 +/+ tumor cells, the amount of Hsp70 membrane-positive cells was significantly reduced after blocking the p53-MDM2 interaction by either PXN727 or Nutlin-3 (Fig. 7b) . Similar effects on Hsp70 membrane levels were observed when A549 lung cancer cells harboring WT p53 were treated with MDM2-inhibitors (Fig. 7b) . MDM2-inhibition did not influence the expression of membrane Hsp70 in p53 depleted HCT116 and mutant p53 FaDu tumor cells (Fig. 7b) . To determine whether the downregulation of membrane Hsp70 by MDM2-inhibition is caused by a release of Hsp70 into the extracellular milieu, the concentration of Hsp70 was (p53 null) tumor cells stained for β-gal after a treatment with DMSO vehicle control (control), PXN727 or Nutlin-3 (10 μM each) after 5 and 8 days, respectively. Senescence is represented by a loss of tumor cells, changes in cell morphology and a blue staining which indicates the expression of β-gal. Scale bar depicts 100 μm measured in cell culture supernatants. A substantial increase of extracellular Hsp70 upon MDM2-inhibition was detected in HCT116 p53 +/+ and A549 cells, but not in HCT116 p53
−/ − and FaDu cells (Fig. 7c) .
Discussion
The tumor suppressor gene p53 is mutated or deleted in approximately 50 % of human cancers. In WT p53 tumors, p53 function is inhibited by the negative regulatory protein MDM2 that is frequently overexpressed in tumor cells and is further increased upon radiation. An impaired p53 function is known to be associated with a reduced sensitivity of tumor cells to radiotherapy (Gudkov and Komarova 2003) . Therefore, blocking the interaction of MDM2 and p53 is a promising approach to stabilize and re-activate the tumor suppressor function of p53. In this study we investigated the radiosensitizing effects of the new small molecule inhibitor PXN727 in isogenic WT and p53 depleted tumor cell lines.
Similar to Nutlin-3, PXN727 increases the protein levels of p53 and its client genes p21 and MDM2 in WT but not mutant p53 tumor cells. Concomitant with the upregulation of p21, PXN727 treatment results in tumor cell growth inhibition, a G 2 /M-arrest and a significant reduction of cells in the radioresistant S-phase in WT p53 tumor cells. Moreover, a combined treatment of WT p53 tumor cells with PXN727 and radiation synergistically enhances the G 2 /Mblock. This indicates that during radiation MDM2 attenuates the p53 functions in the cell cycle. The finding that PXN727 radiosensitizes WT p53 tumor cells but not p53-depleted tumor cells confirmed the dependency of PXN727 on WT p53. Furthermore, we hypothesize that the radiosensitizing effect of PXN727 on WT p53 tumor cells is mainly mediated by senescence but not by apoptosis. An individualized tumor therapy requires determination of the p53 status in tumors to select for those patients who might profit from the radiosensitizing effect of PXN727.
Similar radiosensitizing effects have previously been demonstrated for the MDM2-inhibitor Nutlin-3, which was used as a control in our experiments (Arya et al. 2010; Cao et al. 2006 ). Due to its lower toxicity and better bioavailability, PXN727 might be preferable. Furthermore, Nutlin-3 can induce mutations in WT p53 tumor cells which result in a reduced radiosensitivity and an increased drug resistance (Michaelis et al. 2011) . The induction of p53 mutations is not a general problem of MDM2-inhibitors, since RITA, another MDM2 inhibitor did not reveal these adverse side effects (Michaelis et al. 2012) . With respect to PXN727, further examinations are warranted to investigate long-term effects on the p53-status and radioresistance of tumor cells.
The p53-dependent radiosensitization of HCT116 colon cancer cells by MDM2-inhibitors is associated with a reduced Hsp70 membrane expression. This finding was not expected, since most clinically applied anti-cancer drugs have been shown to increase the Hsp70 membrane expression on tumor cells (Gehrmann et al. 2002) . High Hsp70 membrane levels have been associated with an unfavorable prognosis and increased resistance towards radiochemotherapy (Gehrmann et al. 2003; . Therefore, the downregulation of membrane Hsp70 by MDM2-inhibition might be beneficial regarding the therapeutic response. Moreover, the reduction of membrane Hsp70 by PXN727 was associated with an increased secretion of Hsp70 from tumor cells. Since we have demonstrated previously that extracellular Hsp70 can increase the radiosensitivity of tumor cells by inducing tumor cell death (Schilling et al. 2009 ), this effect might contribute to the radiosensitizing effect of PXN727.
The majority of Hsp70 has been shown to be released from tumor cells not as a free protein but rather in membrane vesicles (Gastpar et al. 2005) . Due to detergents in the dilution buffer, the ELISA detecting Hsp70 does not distinguish between free and vesicular Hsp70. Therefore, it is not possible to address the question whether MDM2-inhibition induces the release of free or vesicular Hsp70. However, we assume that externalized Hsp70 is derived from the plasma membrane, since cytosolic Hsp70 levels remained unaltered upon MDM2-inhibition. p53 activation has been shown to enhance the secretion of membrane vesicles from human WT p53 cancer cells (Lehmann et al. 2008; Yu et al. 2006 ). In addition, p53 activation was reported to elicit an endosomal clearance of growth factor receptors from the plasma membrane with the consequence of an attenuated cell growth (Yu et al. 2009 ). The observed reduction of cell surface Hsp70 levels and increased Hsp70 release upon MDM2-inhibition in WT p53 tumor cells fits into the model of a p53-dependent downregulation of plasma membranelocalized proteins and vesicular secretion.
Since the secretion of Hsp70 was found to be associated with p53-activation and radiosensitization of tumor cells, we speculate that extracellular Hsp70 levels might serve as a biomarker for monitoring and predicting the outcome of patients receiving p53-activating therapeutics. Future experimental approaches using different tumor cell lines and xenograft models are required to confirm this assumption.
